Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by country, state, or city

Search by locations

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “United Kingdom”

A Study to Evaluate ALN-5288 in Patients With Alzheimer's DiseaseRecruiting
NCT07214727Phase 1Updated Aug 14, 2026
Sponsor: Alnylam Pharmaceuticals
Alzheimer's Disease
Canada, Netherlands, Spain, United Kingdom
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other TreatmentsRecruiting
NCT05020236Phase 3Updated Aug 14, 2026
Sponsor: Pfizer
Multiple Myeloma
United States, Argentina, Australia, Austria, Belgium +21 more
Coroflex® ISAR NEO PMCF StudyRecruiting
NCT05698732N/AUpdated Aug 14, 2026
Sponsor: Fundación EPIC
Coronary Artery Disease (CAD) · Ischemic Heart Disease
France, Spain, United Kingdom
A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic DermatitisRecruiting
NCT07277660Phase 2Updated Aug 14, 2026
Sponsor: UCB Biopharma SRL
Atopic Dermatitis
United States, Bulgaria, Canada, Czechia, Germany +4 more
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)Recruiting
NCT07519772Phase 1, Phase 2Updated Aug 14, 2026
Sponsor: Merck Sharp & Dohme LLC
Lymphoma, Non-Hodgkin · Lymphoma, Follicular · Lymphoma, Large B-Cell, Diffuse
United States, Argentina, Australia, Canada, China +7 more
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic DermatitisActive Not Recruiting
NCT06718101Phase 2Updated Aug 14, 2026
Sponsor: AbbVie
Atopic Dermatitis
United States, Japan, South Korea, United Kingdom
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCTRecruiting
NCT07764978Phase 3Updated Aug 14, 2026
Sponsor: AstraZeneca
Newly Diagnosed Multiple Myeloma
United States, Australia, Brazil, Canada, Denmark +10 more
A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial SpondyloarthritisActive Not Recruiting
NCT04436640Phase 3Updated Aug 14, 2026
Sponsor: UCB Biopharma SRL
Axial Spondyloarthritis · Ankylosing Spondylitis · r-axSpa · Nr-axSpa
United States, Belgium, Bulgaria, China, Czechia +9 more
A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically SuppressedRecruiting
NCT07650916Phase 3Updated Aug 14, 2026
Sponsor: ViiV Healthcare
HIV Infections
United States, Argentina, Australia, Canada, Japan +4 more
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 GangliosidosisRecruiting
NCT07054515Phase 3Updated Aug 14, 2026
Sponsor: Azafaros B.V.
Niemann-Pick Type C Disease · GM1 Gangliosidosis · GM2 Gangliosidosis
United States, Argentina, Australia, Brazil, Canada +12 more
A Study of Mezagitamab in Adults With Kidney Condition Called IgA NephropathyRecruiting
NCT06963827Phase 3Updated Aug 14, 2026
Sponsor: Takeda
Kidney Disease
United States, Argentina, Australia, Austria, Canada +21 more
An Open-label Study (OLE) for Non-responders of VRDN-001-101 and VRDN-001-301Completed
NCT06179875Phase 3Updated Aug 14, 2026
Sponsor: Viridian Therapeutics, Inc.
Thyroid Eye Disease
United States, France, Germany, Netherlands, Poland +3 more
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.Recruiting
NCT05609630Phase 3Updated Aug 14, 2026
Sponsor: AbbVie
Juvenile Idiopathic Arthritis
United States, Argentina, Australia, Austria, Brazil +12 more
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)Active Not Recruiting
NCT03742895Phase 2Updated Aug 14, 2026
Sponsor: Merck Sharp & Dohme LLC
Advanced Solid Neoplasms
United States, Argentina, Australia, Canada, Colombia +16 more
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)Recruiting
NCT07007065Phase 3Updated Aug 14, 2026
Sponsor: AbbVie
Neovascular Age-related Macular Degeneration
United States, Austria, Belgium, Bulgaria, Canada +12 more
Exploring Resistance Exercise Training Plus High-Intensity Interval Training (ReHIIT) as Cancer PrehabilitationRecruiting
NCT07313332NAUpdated Aug 14, 2026
Sponsor: University of Nottingham
Healthy Adult Male and Female Volunteers · Intervention
United Kingdom
A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)Recruiting
NCT07489495Phase 3Updated Aug 14, 2026
Sponsor: Merck Sharp & Dohme LLC
Carcinoma, Renal Cell
United States, Argentina, Australia, Brazil, Chile +13 more
Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart FailureRecruiting
NCT06651970Phase 4Updated Aug 14, 2026
Sponsor: AstraZeneca
Chronic Lymphocytic Leukaemia · Moderate to Severe Cardiac Impairment
United States, Czechia, Italy, Poland, Spain +1 more
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)Recruiting
NCT06875310Phase 3Updated Aug 14, 2026
Sponsor: Mirati Therapeutics Inc.
Carcinoma, Non-Small-Cell Lung
United States, Argentina, Australia, Austria, Belgium +30 more
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related ComorbiditiesRecruiting
NCT07743463Phase 3Updated Aug 14, 2026
Sponsor: Ascletis Pharma (China) Co., Limited
Obesity · Overweight · Chronic Weight Management
United States, Canada, Czechia, Germany, Greece +2 more
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOGAD)Active Not Recruiting
NCT05063162Phase 3Updated Aug 14, 2026
Sponsor: UCB Biopharma SRL
Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD)
United States, Australia, Belgium, Brazil, Czechia +15 more
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 DiabetesRecruiting
NCT07743450Phase 3Updated Aug 14, 2026
Sponsor: Ascletis Pharma (China) Co., Limited
Obesity · Overweight · Chronic Weight Management · Type 2 Diabetes Mellitus
United States, Czechia, Germany, Greece, Poland +1 more
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)Recruiting
NCT06312176Phase 3Updated Aug 14, 2026
Sponsor: Merck Sharp & Dohme LLC
Breast Neoplasms
United States, Argentina, Australia, Belgium, Brazil +35 more
Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's LymphomaActive Not Recruiting
NCT06667687Phase 1Updated Aug 14, 2026
Sponsor: AbbVie
Non-Hodgkin's Lymphoma
United States, Australia, Israel, Japan, United Kingdom
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune ThrombocytopeniaRecruiting
NCT06948318Phase 3Updated Aug 14, 2026
Sponsor: Takeda
Immune Thrombocytopenic Purpura (ITP)
United States, Australia, Bulgaria, China, Croatia +10 more

Previous page Next page